Epic Sciences

10.29.2018 / San Diego Back to News Listings

Epic Sciences, Genomic Health Get Medicare LCD for Prostate Cancer Diagnostic

Epic Sciences and Genomic Health announced that Medicare Administrative Contractor Palmetto GBA, has issued a positive final local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test. The final LCD recommends Medicare coverage effective December 10, 2018.

The test helps determine which patients with metastatic castrate resistant prostate cancer (mCRPC) may benefit from continued androgen receptor signaling inhibitor (ARSi) therapy, such as enzalutamide, abiraterone and apalutamide, as well as those who are resistant who may benefit from chemotherapy.

Read the full story on Clinical OMICs.

clinical omics logo.gif